4//SEC Filing
SUN ANTHONY Y 4
Accession 0001725160-22-000006
CIK 0001725160other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 5:49 PM ET
Size
27.6 KB
Accession
0001725160-22-000006
Insider Transaction Report
Form 4
SUN ANTHONY Y
DirectorPresident & CEO
Transactions
- Gift
Common Stock
2021-12-16−15,000→ 1,213,659 total - Sale
Common Stock
2022-01-03$78.26/sh−2,573$201,362→ 1,211,086 total - Sale
Common Stock
2022-01-03$79.18/sh−1,125$89,083→ 1,209,961 total - Sale
Common Stock
2022-01-03$80.36/sh−4,372$351,319→ 1,205,589 total - Sale
Common Stock
2022-01-03$81.14/sh−1,108$89,902→ 1,204,481 total - Sale
Common Stock
2022-01-03$82.18/sh−993$81,604→ 1,203,488 total - Sale
Common Stock
2022-01-03$83.89/sh−300$25,168→ 1,203,188 total - Sale
Common Stock
2022-01-04$77.71/sh−2,000$155,425→ 1,201,188 total - Sale
Common Stock
2022-01-04$78.76/sh−6,871$541,140→ 1,194,317 total - Sale
Common Stock
2022-01-04$79.54/sh−1,556$123,767→ 1,192,761 total - Sale
Common Stock
2022-01-04$80.43/sh−44$3,539→ 1,192,717 total
Holdings
- 125,000(indirect: By Trust)
Common Stock
- 974,302(indirect: By LLC)
Common Stock
- 103,650(indirect: By Spouse)
Common Stock
- 213,600(indirect: By Trust)
Common Stock
Footnotes (13)
- [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021.
- [F10]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $79.26 to $80.13. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F11]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $80.35 to $80.725. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F12]Represents shares nominally held by Hao Bao Zi Trust LLC on behalf of the Hao Bao Zi Trust (the "Trust"), the sole member of Hao Bao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Bao Zi Trust LLC except to the extent of his pecuniary interest therein, if any.
- [F13]Represents shares nominally held by Hao Jiao Zi Trust LLC on behalf of the Hao Jiao Zi Trust (the "Trust"), the sole member of Hao Jiao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Jiao Zi Trust LLC except to the extent of his pecuniary interest therein, if any.
- [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $77.72 to $78.71. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $78.73 to $79.72. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $79.78 to $80.74. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $80.79 to $81.40. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $81.91 to $82.73. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $83.34 to $84.17. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $77.23 to $78.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F9]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $78.24 to $79.23. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Zentalis Pharmaceuticals, Inc.
CIK 0001725160
Entity typeother
Related Parties
1- filerCIK 0001377952
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 5:49 PM ET
- Size
- 27.6 KB